

GALLBLADDER AND BILIARY TRACT DISEASES

- Thoracic empyema due to migrated gallstones 12:325-ih
- Abernethy malformation with multiple aneurysms:
incidentally found in an adult
woman with Caroli's disease 12:327-cr
- Hemorrhagic liver cyst rupture:
An unusual life-threatening complication of
hepatic cyst and literature review 12:336-cr
- Heap of stones:
An unusual cause for biliary colic and
elevated liver function tests 12:493-ih
- Hepatoolithiasis with secondary cholangitis and
supernumerary left hepatic lobe 12:966-ih
- Giant biliary mucinous cystadenoma of the liver 12:979-cr

CIRRHOSIS

- Hepatitis C virus infection in
patients with primary biliary cirrhosis 12:78-oa
- Efficacy and safety of entecavir and/or
tenofovir in hepatitis B compensated and
decompensated cirrhotic patients in clinical practice 12:205-oa
- Mean platelet volume is a useful indicator of
systemic inflammation in cirrhotic patients with
ascitic fluid infection 12:294-oa
- Intestinal mucosal proliferation, apoptosis and
oxidative stress in patients with liver cirrhosis 12:301-oa
- Cirrhosis is less cirrhosis without virus C 12:341-lne
- Serum natremia affects health-related
quality of life in patients with liver cirrhosis:
a prospective, single centre study 12:448-oa
- IGF-I and IGFBP-3 serum levels in patients
hospitalized for complications of liver cirrhosis 12:456-oa
- Decreased serum total T3 level in hepatitis B
and C related cirrhosis by severity of liver damage 12:506-le
- Serum cholesterol is a significant and independent
mortality predictor in liver cirrhosis patients 12:581-oa
- Acute phase proteins for the diagnosis of
bacterial infection and prediction of mortality in
acute complications of cirrhosis 12:599-oa
- Coagulation abnormalities in the cirrhotic patient 12:713-cre
- The X-ray repair cross complementing
protein 1 (XRCC1) rs25487 polymorphism and
susceptibility to cirrhosis in Brazilian patients
with chronic viral hepatitis 12:733-oa
- Rhombencephalitis by *Listeria monocytogenes*
in a cirrhotic patient:
a case report and literature review 12:830-cr

- Defining renal failure in cirrhosis - Acute
kidney injury classification or traditional criteria? 12:984-lne

FIBROSIS

- Diagnostic value of fibronectin discriminant
score for predicting liver fibrosis stages in
chronic hepatitis C virus patients 12:44-oa
- Liver fibrosis in young Egyptian beta-thalassemia
major patients: relation to hepatitis C virus
and compliance with chelation 12:54-oa
- Association of amino acid imbalance with
the severity of liver fibrosis and esophageal varices 12:471-oa
- Non-invasive assessment of liver fibrosis with
transient elastography (FibroScan®):
applying the cut-offs of M probe to XL probe 12:570-oa
- Non-invasive assessment of
liver fibrosis using ARFI with pathological correlation,
a prospective study 12:608-oa
- Noninvasive assessment of hepatic fibrosis
using gadoxetate-disodium-enhanced 3T MRI 12:926-oa
- ARFI cut-off values and significance of
standard deviation for liver fibrosis staging in
patients with chronic liver disease 12:935-oa
- Non-invasive assessment of
liver steatosis and fibrosis in HIV/HCV- and
HCV- infected patients 12:740-oa
- Validation study of systems for
noninvasive diagnosis of fibrosis in nonalcoholic
fatty liver disease in Latin population 12:416-oa

VIRAL HEPATITIS

- Safety and efficacy of treatment with
pegylated interferon alpha-2a with ribavirin in
chronic hepatitis C genotype 4 12:30-oa
- Long-term follow-up of hepatitis C virus-positive
patients with persistently normal serum transaminases 12:36-oa
- Patients younger than forty years old
with hepatitis C virus genotype-1
chronic infection had treatment responses
similar to genotype-2 infection and not
related to interleukin-28B polymorphism 12:62-oa
- Raloxifene Hydrochloride as hepatitis C treatment 12:164-lne
- Prediction of minimal residual viremia in
HCV type 1 infected patients receiving
interferon-based therapy 12:190-oa
- Vitamin D deficiency and vitamin D
therapy in chronic hepatitis C 12:199-oa
- Prevalence and risk factors of isolated
anti-HBc antibody and occult hepatitis B
infection in hemodialysis patients: a nationwide study 12:213-oa

- Single nucleotide polymorphisms in CXCR1 gene and its association with hepatitis B infected patients in Saudi Arabia 12:220-oa
- Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection 12:228-oa
- Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial 12:248-oa
- Isolated granulomatous hepatitis-A histopathological surprise mimicking cholangiocarcinoma in ulcerative colitis 12:332-cr
- Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy 12:373-oa
- Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review 12:380-oa
- Poor response to hepatitis C treatment in elderly patients 12:392-oa
- Impact of sustained virologic response on quality of life in chronic HCV carriers 12:399-oa
- Differential expression of transforming growth factor- β 1 and HBx enhances hepatitis B virus replication and augments host immune cytokines and chemokines 12:408-oa
- Occult hepatitis B in patients on hemodialysis: a review 12:527-cre
- Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit 12:532-oa
- High frequencies of CD158b⁺ NK cells are associated with persistent hepatitis C virus infections 12:539-oa
- Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-Two case reports 12:629-cr
- Use of proteomic analysis tools to identify HCV-proteins down-regulated by acetylsalicylic acid 12:725-oa
- Syncope during boceprevir treatment in hepatitis C 12:837-le
- Treatment of chronic hepatitis C virus infection in the near future 12:854-ed
- Hepatitis E virus: new faces of an old infection 12:861-cre
- Prevalence of insulin resistance in chronic hepatitis C genotype 1 and 3 patients 12:871-oa
- An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver 12, suppl.2: S3

HEPATOBIILIARY MALIGNANCIES

- Focal nodular hyperplasia and hepatic regenerating nodules in pediatric oncology patients: how much invasive approach is necessary? 12:308-oa
- Hepatic carcinosarcoma: clinicopathologic features and a review of the literature. 12:495-cr

HEPATOCELLULAR CARCINOMA

- Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis 12:142-cr
- Epidemiology of hepatocellular carcinoma in sub-Saharan Africa 12:173-cre
- Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease 12:236-oa
- Comparison of prognosis by viral etiology in patients with hepatocellular carcinoma after radiofrequency ablation 12:263-oa
- Hepatocellular carcinoma arising in a telangiectatic hepatocellular adenoma 12:626-ih
- Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients 12:766-oa
- Caspase recruitment domains. New potential markers for diagnosis of hepatocellular carcinoma associated with HCV in Egyptian patients 12:774-oa
- Hepatocellular carcinoma that arose from primary Sjögren's syndrome 12:824-cr
- Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging 12:915-oa
- Portal venous tumor growth-type of hepatocellular carcinoma without liver parenchyma tumor nodules: a case report 12:969-cr

HEPATOTOXICITY

- Herbal hepatotoxicity and WHO global introspection method 12:11-cre
- Spondias pinnata* stem bark extract lessens iron overloaded liver toxicity due to hemosiderosis in Swiss albino mice 12:123-oa
- Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report 12:152-cr
- Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population 12:959-oa

VASCULAR DISORDERS

- Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage 12:22-cre

Transjugular intrahepatic portosystemic shunt is associated with significant changes in mitral inflow parameters 12:464-oa

Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables 12:588-oa

Within-patient temporal variance in MELD score and impact on survival prediction after TIPS creation 12:797-oa

Aspartate aminotransferase-to-platelet ratio index (APRI) for the non-invasive prediction of esophageal varices 12:810-oa

LIVER FAILURE

Use of acetylcysteine for non-acetaminophen-induced acute liver failure 12:6-cre

The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis 12:364-oa

Liver failure unmasks celiac disease in a child 12:501-cr

Predicting the prognosis in acute liver failure: results from a retrospective pilot study using the LiMAX test 12:556-oa

Acute liver failure in under two year-olds - are there markers of metabolic disease on admission? 12:791-oa

Subacute liver failure by pseudocirrhotic metastatic breast cancer infiltration 12:834-cr

NONALCOHOLIC FATTY LIVER DISEASE

Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study 12:70-oa

Probiotics: a possible role in treatment of adult and pediatric non alcoholic fatty liver disease 12:161-le

Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study 12:256-oa

Probiotics in non-alcoholic fatty liver disease: which and when 12:357-cre

Dendritic cells in NASH: Friend or foe? 12:508-lne
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease ... 12:548-oa

The fate of fatty liver disease: of bile and fatty acids 12:642-lne

Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index 12:749-oa

Primary care practitioners survey of non-alcoholic fatty liver disease 12:758-oa
Metabolic syndrome and nonalcoholic fatty liver disease. The role of endothelial progenitor cells 12:908-oa

LIVER TRANSPLANTATION

First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder 12:156-cr

Comparison of results of combined liver-kidney transplantation vs. isolated liver transplantation 12:274-oa

A Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection 12:282-oa

Impact of creatinine values on MELD scores in male and female candidates for liver transplantation 12:434-oa

Impact of MELD score implementation on liver allocation: experience at a Brazilian center 12:440-oa

Sirolimus based immunosuppression is associated with need for early repeat therapeutic ERCP in liver transplant patients with anastomotic biliary stricture 12:563-oa

Liver retransplantation in adults: a 20-year experience of one center in southern Brazil 12:942-oa

Impact of untreated portal vein thrombosis on pre and post liver transplant outcomes in cirrhosis 12:952-oa

Haemophagocytic syndrome in a liver transplant patient during treatment with Telaprevir 12:974-cr

MISCELLANEOUS

Impact of the severity of end-stage liver disease in cardiac structure and function 12:85-oa

High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome 12:92-oa

Feasibility and reliability of the FibroScan S2 (pediatric) probe compared with the M probe for liver stiffness measurement in small adults with chronic liver disease 12:100-oa

How to diagnose hepatic encephalopathy in the emergency department 12:108-oa

Granulomatous hepatitis caused by Q fever: a differential diagnosis of fever of unknown origin 12:138-ih

Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? 12:147-cr

- S-adenosylmethionine metabolism and liver disease 12:183-cre
- Cardiac changes and liver disease 12:340-le
- Minimal hepatic encephalopathy. Should we treat it? 12:487-ed
- The *Annals of Hepatology* welcomes the Canadian Association for the Study of the Liver (CASL) 12:522-ed
- Unexpected discovery of massive liver echinococcosis. A clinical, morphological, and functional diagnosis 12:634-cr
- We are all trying to predict what we don't know! 12:710-hh
- Treatment of polycystic liver disease: a hypothesis, patient characteristics, short and long-term results 12:782-oa
- Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine 12:803-oa
- A giant calcified hepatic mass 12:822-ih
- Liver stiffness measurements increase after meal ingestion - an important step towards standardization 12:839-lne
- Alcohol, liver and genes: an intricate puzzle 12:860-hh
- Percutaneous liver biopsy - 2 decades of experience in a public hospital in the South of Brazil 12:876-oa
- Hormonal pretreatment preserves liver regenerative capacity and minimizes inflammation after partial hepatectomy 12:881-oa
- Genetic factors affecting susceptibility to alcoholic liver disease in an Indian population 12:901-oa
- ## BASIC STUDIES
- Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat 12:115-oa
- Evidence that estrogen receptors play a limited role in mediating enhanced recovery of bile flow in female rats in the acute phase of liver ischemia reperfusion injury 12:130-oa
- A metal mixture induces transformation upon antioxidant depletion in a hepatic cell line 12:315-oa
- The effect of celecoxib on the development of diethylnitrosamine-induced liver tumors in rats 12:425-oa
- PGE₂ induces MUC2 and MUC5AC expression in human intrahepatic biliary epithelial cells via EP4/p38MAPK activation 12:479-oa
- Pegylated interferon- α 2b and ribavirin decrease claudin-1 and E-cadherin expression in HepG2 and Huh-7.5 cells 12:616-oa
- Notch signal protects non-parenchymal cells from ischemia/reperfusion injury *in vitro* by repressing ROS 12:815-oa
- Pioglitazone upregulates hepatic angiotensin converting enzyme 2 expression in rats with steatohepatitis 12:892-oa